Evidence map›Paper›PMID 40563347›Full record

ReviewAntioxidants (Basel, Switzerland)2025

Astaxanthin: A Compound in the Prevention of Chronic Diseases and as a Potential Adjuvant Treatment Agent.

Xiao Zhu, Xi Chen, Matthew Wang, Honghua Hu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Antioxidants (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xiao ZhuSchool of Medicine, Jinhua University of Vocational Technology, Jinhua 321017, China.
Xi ChenInnovation Center of Translational Pharmacy, Jinhua Institute of Zhejiang University, Jinhua 321016, China.
Matthew WangFaculty of Medicine and Health, University of New South Wales, Sydney, NSW 2052, Australia.
Honghua HuInnovation Center of Translational Pharmacy, Jinhua Institute of Zhejiang University, Jinhua 321016, China.ORCID 0000-0002-3749-4089

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Astaxanthin (AST) is a fat-soluble carotenoid antioxidant. AST exhibits multiple protective mechanisms, including its antioxidant, anti-inflammatory, immunomodulatory, anti-apoptotic, nervous system-protective, anti-tumor, and anti-fibrotic effects. These effects make it a promising compound for the prevention of chronic diseases. AST can protect the nervous system against neurodegenerative diseases such as Alzheimer's and Parkinson's disease. It also protects the liver and helps reduce the risk of chronic kidney disease. Additionally, it improves cardiovascular health and has anti-diabetic properties. This review aims to provide an updated overview covering the protective effects of AST against various chronic diseases, including its antioxidant, anti-inflammatory, and anti-apoptotic effects. We also discuss the strategies used for improving astaxanthin bioavailability and its potential as an adjuvant therapeutic agent.

Indexed as

anti-apoptosisanti-inflammatoryantioxidationanti-tumorastaxanthinchronic diseasesimmune regulation

Identifiers

PMID40563347
PMCPMC12189495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.